Livagen
Lab-Tested ≥98% Purity · Certificate of Analysis Included · Global Shipping
Livagen (Lys-Glu-Ala-Ser) — Hepatic Bioregulator Peptide for Liver Research
Livagen is a synthetic tetrapeptide bioregulator (Lys-Glu-Ala-Ser) developed at the St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson. This liver-specific bioregulator has been extensively characterized for its capacity to modulate hepatocyte gene expression, restore liver detoxification enzyme activity, and normalize hepatic regenerative capacity in aged and chemically challenged liver tissue models. Published research in Bulletin of Experimental Biology and Medicine has documented its unique mechanism of chromatin decondensation in hepatocyte nuclei.
Mechanism of Action
Livagen represents one of the most thoroughly studied Khavinson bioregulators at the molecular level. The KEAS tetrapeptide has been demonstrated to induce decondensation of heterochromatin in hepatocyte nuclei, reactivating previously silenced gene regions. Specifically, research using atomic force microscopy and FISH analysis has shown that Livagen promotes unfolding of pericentromeric satellite DNA regions, increasing transcriptional accessibility at loci encoding cytochrome P450 enzymes (CYP1A2, CYP3A4), glutathione S-transferase isoforms, and albumin synthesis machinery.
Key Research Areas
- Chromatin Remodeling: Landmark studies have demonstrated that Livagen induces measurable chromatin decondensation in hepatocyte nuclei within hours of treatment, increasing the proportion of transcriptionally active euchromatin—a finding confirmed by both DAPI staining and DNase I hypersensitivity assays.
- Hepatic Detoxification: Research has shown normalization of cytochrome P450 enzyme activity profiles in aged hepatocyte cultures, with significant restoration of CYP1A2 and CYP3A4 catalytic capacity following Livagen treatment.
- Liver Regeneration: Partial hepatectomy models have demonstrated enhanced regenerative response in Livagen-pretreated animals, with increased hepatocyte proliferation rates (Ki-67 positivity) and preserved lobular architecture during regrowth.
- Hepatoprotection: Studies in CCl₄-induced liver injury models have shown reduced transaminase elevation, decreased oxidative stress markers (MDA, 4-HNE), and preserved glutathione reserves following Livagen administration.
Technical Specifications
- Dosage per vial: 10mg lyophilized powder
- Purity: ≥98% (HPLC verified)
- Sequence: Lys-Glu-Ala-Ser (KEAS tetrapeptide)
- Molecular Weight: 433.46 Da
- Storage: -20°C, protected from light
Why Researchers Choose Peptides BioLab
Every batch of Livagen supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our product is supplied as a lyophilized powder for maximum stability, shipped worldwide in temperature-controlled packaging.
Related Research Peptides
Researchers studying hepatic bioregulation and liver biology may also find these compounds relevant: BPC-157, Thymalin, and NAD+. For a complete overview, browse our Recovery Research collection.
For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.
Every Peptides BioLab product includes a Certificate of Analysis (CoA) with HPLC and MS data confirming ≥98% purity. The CoA is available in the product tabs as the 2nd image, or contact our team to request a copy.
Shipping: We ship worldwide from our state-of-the-art facilities. Orders are processed within 1–2 business days. Express and standard shipping options available at checkout.
Storage: Store lyophilized peptides at -20°C for long-term storage. Once reconstituted, store at 2–8°C and use within 30 days. Keep away from direct sunlight.
